United Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

United Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 7% bzw. 7.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.6% betragen.

Wichtige Informationen

7.0%

Wachstumsrate der Gewinne

5.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	7.3%
Zukünftige Eigenkapitalrendite	12.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04

United Therapeutics Q2 2022 Earnings Preview

Aug 02

These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely

Jul 17

United Therapeutics reaches all-time high; shares up 15% YTD

Jul 06

Why Hold United Therapeutics After Shares Doubled?

Jun 08

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting

May 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:UTHR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,159	1,313	1,331	1,618	12
12/31/2025	2,965	1,292	1,141	1,431	15
12/31/2024	2,737	1,187	1,073	1,584	15
3/31/2024	2,498	1,051	752	980	N/A
12/31/2023	2,328	985	748	978	N/A
9/30/2023	2,204	900	764	956	N/A
6/30/2023	2,111	872	674	868	N/A
3/31/2023	1,981	728	722	889	N/A
12/31/2022	1,936	727	664	803	N/A
9/30/2022	1,860	707	679	849	N/A
6/30/2022	1,789	631	652	776	N/A
3/31/2022	1,768	687	673	797	N/A
12/31/2021	1,686	476	477	598	N/A
9/30/2021	1,655	462	487	550	N/A
6/30/2021	1,591	471	560	615	N/A
3/31/2021	1,506	405	574	631	N/A
12/31/2020	1,483	515	696	756	N/A
9/30/2020	1,410	469	660	732	N/A
6/30/2020	1,431	430	597	667	N/A
3/31/2020	1,443	528	564	635	N/A
12/31/2019	1,449	-104	-290	-207	N/A
9/30/2019	1,519	-92	-334	-224	N/A
6/30/2019	1,530	-118	-310	-172	N/A
3/31/2019	1,601	-150	-297	-125	N/A
12/31/2018	1,628	589	594	778	N/A
9/30/2018	1,711	543	447	607	N/A
6/30/2018	1,744	713	487	628	N/A
3/31/2018	1,744	484	411	519	N/A
12/31/2017	1,725	418	N/A	474	N/A
9/30/2017	1,670	509	N/A	723	N/A
6/30/2017	1,632	395	N/A	694	N/A
3/31/2017	1,600	657	N/A	749	N/A
12/31/2016	1,599	714	N/A	644	N/A
9/30/2016	1,595	708	N/A	506	N/A
6/30/2016	1,573	1,011	N/A	484	N/A
3/31/2016	1,507	904	N/A	400	N/A
12/31/2015	1,466	652	N/A	383	N/A
9/30/2015	1,407	663	N/A	448	N/A
6/30/2015	1,351	173	N/A	449	N/A
3/31/2015	1,327	186	N/A	354	N/A
12/31/2014	1,289	340	N/A	355	N/A
9/30/2014	1,231	194	N/A	369	N/A
6/30/2014	1,203	282	N/A	300	N/A
3/31/2014	1,161	250	N/A	438	N/A
12/31/2013	1,117	175	N/A	425	N/A
9/30/2013	1,070	288	N/A	426	N/A
6/30/2013	1,010	304	N/A	380	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: UTHRDas prognostizierte Gewinnwachstum (7% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: UTHRDie Erträge des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: UTHRDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: UTHRDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: UTHRDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: UTHRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.6%).

United Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to US$278

Price target increased to US$273

Consensus forecasts updated

Consensus EPS estimates increase by 18%

Recent updates

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

First quarter 2024 earnings released: EPS: US$6.52 (vs US$5.20 in 1Q 2023)

United Therapeutics Corporation to Report Q1, 2024 Results on May 01, 2024

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics Corporation (NasdaqGS:UTHR) announces an Equity Buyback for $1,000 million worth of its shares.

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Independent Director exercised options and sold US$2.1m worth of stock

New minor risk - Insider selling

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Executive VP exercised options and sold US$585k worth of stock

United Therapeutics Corporation to Report Q4, 2023 Results on Feb 21, 2024

Executive VP notifies of intention to sell stock

Executive VP exercised options and sold US$606k worth of stock

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Executive VP notifies of intention to sell stock

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Executive VP notifies of intention to sell stock

United Therapeutics Corporation Announces U.S. Court of Appeals for the Federal Circuit Issues A Decision Regarding Company's U.S. Patent No. 10,716,793

United Therapeutics Corporation (NasdaqGS:UTHR) completed the acquisition of Miromatrix Medical Inc. (NasdaqCM:MIRO) from Gagnon Securities, LLC and others

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Independent Director exercised options and sold US$764k worth of stock

Executive VP notifies of intention to sell stock

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Executive VP notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

United Therapeutics Corporation (NasdaqGS:UTHR) entered into definitive agreement to acquire Miromatrix Medical Inc. (NasdaqCM:MIRO) from shareholders for $89.1 million.

United Therapeutics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Executive VP notifies of intention to sell stock

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

United Therapeutics Corporation to Report Q2, 2023 Results on Aug 02, 2023

United Therapeutics Corporation to Report Q2, 2023 Results on Aug 02, 2023

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive VP exercised options and sold US$645k worth of stock

Executive VP exercised options and sold US$533k worth of stock

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Insider recently sold US$80k worth of stock

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Full year 2022 earnings: EPS and revenues miss analyst expectations

United Therapeutics Corporation to Report Q4, 2022 Results on Feb 22, 2023

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Insider recently sold US$285k worth of stock

Insider recently sold US$159k worth of stock

Price target increased to US$278

Insufficient new directors

Insider recently sold US$78k worth of stock

Price target increased to US$273

United Therapeutics Announces Top Line Data from the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy

United Therapeutics Corporation to Report Q3, 2022 Results on Nov 02, 2022

Executive VP notifies of intention to sell stock

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics Announces First Patient Enrolled in Phase 3 Teton 2 Study of Tyvaso in Patients with Idiopathic Pulmonary Fibrosis

Insider recently sold US$262k worth of stock

Executive VP notifies of intention to sell stock

Board Member exercised options and sold US$479k worth of stock

Board Member exercised options and sold US$610k worth of stock

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Key Executive exercised options and sold US$437k worth of stock

Consensus forecasts updated